These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 9543129

  • 1. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C, Oriente P, Laan R, Hughes RA, Ittner J, Goemaere S, Di Munno O, Pouillès JM, Horlait S, Cortet B.
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
    [Abstract] [Full Text] [Related]

  • 2. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, Kendler DL, Lentle B, Olszynski W, Ste-Marie LG, Tenenhouse A, Chines AA.
    N Engl J Med; 1997 Aug 07; 337(6):382-7. PubMed ID: 9241127
    [Abstract] [Full Text] [Related]

  • 3. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD, Roux C, Pitt PI, Cooper C, Moniz C, Dequeker J, Ioannidis G, Cawley MI, Jenkins EA, Walker-Bone KE, Pack S, Stephenson GF, Laan RF, Brown J, Geusens P.
    J Rheumatol; 2000 Oct 07; 27(10):2424-31. PubMed ID: 11036840
    [Abstract] [Full Text] [Related]

  • 4. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.
    J Rheumatol; 2008 Jan 07; 35(1):142-6. PubMed ID: 18050368
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
    Cortet B, Hachulla E, Barton I, Bonvoisin B, Roux C.
    Rev Rhum Engl Ed; 1999 Apr 07; 66(4):214-9. PubMed ID: 10339777
    [Abstract] [Full Text] [Related]

  • 6. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ, Ioannidis G, Adachi JD, Bensen WG, Bianchi F, Cividino A, Gordon M, Kaminska E, Scocchia T, Petrie A, Stephenson GF, Goldsmith CH.
    J Rheumatol; 1999 Jul 07; 26(7):1545-9. PubMed ID: 10405943
    [Abstract] [Full Text] [Related]

  • 7. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A, Snelder AA, Mulder H.
    Am J Med; 1995 Sep 07; 99(3):235-42. PubMed ID: 7653482
    [Abstract] [Full Text] [Related]

  • 8. A double blind placebo controlled study to determine the effects of intermittent cyclical etidronate on bone mineral density in patients on long-term oral corticosteroid treatment.
    Pitt P, Li F, Todd P, Webber D, Pack S, Moniz C.
    Thorax; 1998 May 07; 53(5):351-6. PubMed ID: 9708225
    [Abstract] [Full Text] [Related]

  • 9. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A.
    J Rheumatol; 1994 Oct 07; 21(10):1922-6. PubMed ID: 7837160
    [Abstract] [Full Text] [Related]

  • 10. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
    Geusens P, Dequeker J, Vanhoof J, Stalmans R, Boonen S, Joly J, Nijs J, Raus J.
    Ann Rheum Dis; 1998 Dec 07; 57(12):724-7. PubMed ID: 10070271
    [Abstract] [Full Text] [Related]

  • 11. Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study.
    Wolfhagen FH, van Buuren HR, den Ouden JW, Hop WC, van Leeuwen JP, Schalm SW, Pols HA.
    J Hepatol; 1997 Feb 07; 26(2):325-30. PubMed ID: 9059953
    [Abstract] [Full Text] [Related]

  • 12. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA.
    Arthritis Rheum; 1999 Nov 07; 42(11):2309-18. PubMed ID: 10555025
    [Abstract] [Full Text] [Related]

  • 13. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.
    J Rheumatol; 2003 Dec 07; 30(12):2673-9. PubMed ID: 14719212
    [Abstract] [Full Text] [Related]

  • 14. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I, Herd RJ, Blake GM, Balena R.
    Calcif Tissue Int; 2000 May 07; 66(5):348-54. PubMed ID: 10773104
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec 07; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP.
    J Bone Miner Res; 2000 Jun 07; 15(6):1006-13. PubMed ID: 10841169
    [Abstract] [Full Text] [Related]

  • 17. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

  • 18. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T, Maekawa S, Morinobu S, Morinobu A, Koshiba M, Yamauchi M, Sugimoto T, Kumagai S.
    Ryumachi; 2002 Aug 12; 42(4):666-75. PubMed ID: 12355861
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.